1. Do COX-2 inhibitors reduce metachronous cancer development?

   • Joseph R. Pisegna

   Clinical Trials Report 29 November 2009 Pages: 429 - 430

2. Gastric acid hypersecretory states: Recent insights and advances

   • Nauramy Osefo
   • Tetsuhide Ito
   • Robert T. Jensen

   OriginalPaper 29 November 2009 Pages: 433 - 441

3. Gut sensing mechanisms

   • Arushi deFonseka
   • Jonathan Kaunitz

   OriginalPaper 29 November 2009 Pages: 442 - 447

4. Regulation of food intake: The gastric X/A-like endocrine cell in the spotlight

   • Andreas Stengel
   • Yvette Taché

   OriginalPaper 29 November 2009 Pages: 448 - 454

5. Gastric infection by Helicobacter pylori

   • George Sachs
   • Yi Wen
   • David R. Scott

   OriginalPaper 29 November 2009 Pages: 455 - 461

6. Gastric acid inhibition in the treatment of peptic ulcer hemorrhage

   • Kevin A. Ghassemi
   • Thomas O. G. Kovacs
   • Dennis M. Jensen

   OriginalPaper 29 November 2009 Pages: 462 - 469

7. Insights into IBD pathogenesis

   • David Q. Shih
   • Stephan R. Targan

   OriginalPaper 29 November 2009 Pages: 473 - 480

8. Natural history and complications of IBD

   • Morten H. Vatn

   OriginalPaper 29 November 2009 Pages: 481 - 487

9. Diagnostic advances in inflammatory bowel disease (imaging and laboratory)

   • Maria E. Moscandrew
   • Edward V. Loftus Jr

   OriginalPaper 29 November 2009 Pages: 488 - 495

10. Optimizing conventional therapies for inflammatory bowel disease

    • Miles P. Sparrow
    • Peter M. Irving
    • Stephen B. Hanauer

    OriginalPaper 29 November 2009 Pages: 496 - 503

11. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease)

    • Marc Ferrante
    • Geert D’Haens
    • Gert Van Assche

    OriginalPaper 29 November 2009 Pages: 504 - 508

12. Managing the risks of IBD therapy

    • Cynthia H. Seow
    • Shanika de Silva
    • Remo Panaccione

    OriginalPaper 29 November 2009 Pages: 509 - 517